Dr. Hassan on FLAURA Trial Results in EGFR-Mutant NSCLC

Video

Khaled A. Hassan, MD, MS, discusses the results of the FLAURA trial, which compared osimertinib with first-generation TKIs in patients with EGFR-mutant metastatic non–small cell lung cancer.

Khaled A. Hassan, MD, MS, a medical oncologist at the University of Michigan Rogel Cancer Center, discusses the results of the FLAURA trial, which compared osimertinib (Tagrisso) with first-generation TKIs in patients with EGFR-mutant metastatic non—small cell lung cancer (NSCLC).

The FLAURA trial changed the management of patients with EGFR-driven cancers, explains Hassan. The trial showed a significant improvement in progression-free survival with osimertinib at 18.9 months versus 10.2 months with the first-generation EGFR TKIs erlotinib (Tarceva) or gefitinib (Iressa). There was also activity in patients with brain metastases compared with first-generation EGFR TKIs. Additionally, toxicity levels were low with osimertinib.

At the 2019 ESMO Congress, overall survival data showed a significant improvement with osimertinib at 38 months compared with 31 months with the first-generation TKIs. At 3 years, around 28% of patients were still taking osimertinib versus 9% of patients who received standard EGFR TKIs. These data solidify the role of osimertinib as a first-line treatment for patients with EGFR mutations, meaning any trial looking at patients with EGFR-mutant NSCLC moving forward should have osimertinib as the control arm, Hassan concludes.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,